Matinas BioPharma Holdings (MTNB) Operating Expenses (2013 - 2026)

Over the trailing twelve months to Jun 30, 2026, Matinas BioPharma Holdings reported Operating Expenses of $6.67 million, down 59.9% year-over-year; for FY2025, it was $6.96 million, down 71.7% from FY2024.

• Operating Expenses has declined in each of the last three years, with a five-year compound annual growth rate of -22.2% (FY2020 to FY2025).
• Going back by year, Operating Expenses was $24.59 million in FY2024 (-1.1%), $24.86 million in FY2023 (-10.5%), $27.78 million in FY2022 (+12.2%) and $24.77 million in FY2021 (+1.7%).
• The Q2 2026 figure represents the lowest quarterly Operating Expenses since Q3 2013.
• Year-over-year, Operating Expenses has declined for six consecutive quarters, with an average decline of 35.2% over the last eight quarters.
• The fastest year-over-year change in Operating Expenses over five years came in Q2 2022 (growth of 45.9%), and the weakest in Q4 2025 (a decline of 81.1%).
• Business Quant data shows MTNB's Operating Expenses at $1.94 million (Q1 2026), $1.6 million (Q4 2025) and $1.58 million (Q3 2025) in the three quarters before Q2 2026.